JP2021532155A - トロスピウムを使用した過活動膀胱の治療方法 - Google Patents

トロスピウムを使用した過活動膀胱の治療方法 Download PDF

Info

Publication number
JP2021532155A
JP2021532155A JP2021504826A JP2021504826A JP2021532155A JP 2021532155 A JP2021532155 A JP 2021532155A JP 2021504826 A JP2021504826 A JP 2021504826A JP 2021504826 A JP2021504826 A JP 2021504826A JP 2021532155 A JP2021532155 A JP 2021532155A
Authority
JP
Japan
Prior art keywords
trospium
bladder
individual
day
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021504826A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021532155A5 (https=
JPWO2020028554A5 (https=
Inventor
ギーシング,デニス
Original Assignee
タリス バイオメディカル エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by タリス バイオメディカル エルエルシー filed Critical タリス バイオメディカル エルエルシー
Publication of JP2021532155A publication Critical patent/JP2021532155A/ja
Publication of JP2021532155A5 publication Critical patent/JP2021532155A5/ja
Publication of JPWO2020028554A5 publication Critical patent/JPWO2020028554A5/ja
Priority to JP2024121447A priority Critical patent/JP2024164020A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/468-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0034Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A61M31/002Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/06Anti-spasmodics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00General characteristics of the apparatus
    • A61M2205/02General characteristics of the apparatus characterised by a particular materials
    • A61M2205/0216Materials providing elastic properties, e.g. for facilitating deformation and avoid breaking
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00General characteristics of the apparatus
    • A61M2205/02General characteristics of the apparatus characterised by a particular materials
    • A61M2205/0266Shape memory materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2210/00Anatomical parts of the body
    • A61M2210/10Trunk
    • A61M2210/1078Urinary tract
    • A61M2210/1085Bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2021504826A 2018-08-01 2019-07-31 トロスピウムを使用した過活動膀胱の治療方法 Pending JP2021532155A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024121447A JP2024164020A (ja) 2018-08-01 2024-07-26 トロスピウムを使用した過活動膀胱の治療方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862713414P 2018-08-01 2018-08-01
US62/713,414 2018-08-01
US201962850481P 2019-05-20 2019-05-20
US62/850,481 2019-05-20
PCT/US2019/044478 WO2020028554A1 (en) 2018-08-01 2019-07-31 Methods of treating overactive bladder using trospium

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024121447A Division JP2024164020A (ja) 2018-08-01 2024-07-26 トロスピウムを使用した過活動膀胱の治療方法

Publications (3)

Publication Number Publication Date
JP2021532155A true JP2021532155A (ja) 2021-11-25
JP2021532155A5 JP2021532155A5 (https=) 2022-08-10
JPWO2020028554A5 JPWO2020028554A5 (https=) 2022-08-10

Family

ID=69232612

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021504826A Pending JP2021532155A (ja) 2018-08-01 2019-07-31 トロスピウムを使用した過活動膀胱の治療方法
JP2024121447A Pending JP2024164020A (ja) 2018-08-01 2024-07-26 トロスピウムを使用した過活動膀胱の治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024121447A Pending JP2024164020A (ja) 2018-08-01 2024-07-26 トロスピウムを使用した過活動膀胱の治療方法

Country Status (10)

Country Link
US (2) US11464734B2 (https=)
EP (1) EP3829582A4 (https=)
JP (2) JP2021532155A (https=)
KR (1) KR20210039403A (https=)
CN (1) CN112839653A (https=)
AU (1) AU2019315957A1 (https=)
BR (1) BR112021001337A2 (https=)
CA (1) CA3107461A1 (https=)
MX (1) MX2021001264A (https=)
WO (1) WO2020028554A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT4124339T (lt) 2014-03-06 2025-11-10 Vaisto įvedimo sistemos ir būdai šlapimo pūslės vėžiui gydyti gemcitabinu
BR112020000832A2 (pt) 2017-07-25 2020-07-21 Taris Biomedical Llc métodos para tratar metástase tumoral
JOP20200124A1 (ar) 2017-11-08 2020-05-20 Taris Biomedical Llc طُرق لعلاج سرطان المثانة باستخدام جيمسيتابين وعلاج مدوامة لذلك
CN112839653A (zh) 2018-08-01 2021-05-25 塔里斯生物医药公司 使用曲司氯铵治疗膀胱过度活动症的方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007517912A (ja) * 2004-01-13 2007-07-05 バソジェニックス ファーマシューティカルズ, インコーポレイテッド 心脈管および腎臓の適応症のための制御放出cgrp送達組成物
JP2008517031A (ja) * 2004-10-20 2008-05-22 ガルデルマ・リサーチ・アンド・デヴェロップメント 座瘡の維持療法におけるアダパレンの使用方法
JP2013534923A (ja) * 2010-06-22 2013-09-09 テバ ウィメンズ ヘルス インコーポレイテッド 過活動膀胱に関連する状態を治療する方法
JP2015529688A (ja) * 2012-09-18 2015-10-08 タリス バイオメディカル エルエルシー トロスピウムの使用による膀胱排尿機能障害及び他の下部尿路疾患の治療のための薬物送達システム及び方法
WO2017042370A1 (en) * 2015-09-10 2017-03-16 Assistance Publique - Hôpitaux De Paris Use of interleukin 2 for treating spondyloarthritis
JP2018070660A (ja) * 2016-10-27 2018-05-10 Eaファーマ株式会社 逆流性食道炎の再発抑制剤

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2125696T3 (es) * 1996-11-27 1999-03-01 Pfleger R Chem Fab Utilizacion del cloruro de tropsio para la produccion de una preparacion farmaceutica para el tratamiento de disfunciones vesicales.
US20060058777A1 (en) 2002-12-11 2006-03-16 Pia Norup Nielsen Urinary catheter device with a pharmaceutically active composition
WO2004064789A2 (en) 2003-01-16 2004-08-05 University Of Rochester Quaternary antimuscarinic compounds for the treatment of bladder diseases
ES2322148T3 (es) 2004-08-11 2009-06-17 BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG Medicamentos que contienen anticolinergicos para el tratamiento en las vias urinarias.
WO2006101954A2 (en) * 2005-03-17 2006-09-28 Indevus Pharmaceuticals, Inc. Interstitial cystitis treatment
US7390816B2 (en) * 2005-06-21 2008-06-24 Bridge Pharma, Inc. Methods for treating urinary incontinence in patients suffering from memory disorders
DK1933810T3 (da) 2005-08-11 2013-01-28 Childrens Medical Center Intravesikal lægemiddelafgivelsesindretning og fremgangsmåde
ES2365161T3 (es) 2005-09-02 2011-09-23 Theravida, Inc. Terapia para el tratamiento de la vejiga hiperactiva.
EP1967202A1 (en) 2007-03-05 2008-09-10 AEterna Zentaris GmbH Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity
KR101538748B1 (ko) 2007-12-11 2015-07-22 메사추세츠 인스티튜트 오브 테크놀로지 이식형 의약 투여 장치와 방광과 기타 신체 낭 또는 내강의 치료 방법
EA201170297A1 (ru) 2008-08-09 2011-08-30 Массачусетс Инститьют Оф Текнолоджи Имплантируемое устройство для доставки лекарственных средств и способ лечения мужской мочеполовой системы и окружающих тканей
DK2445570T3 (da) 2009-06-26 2013-02-25 Taris Biomedical Inc Implanterbare lægemiddelafgivelsesindretninger samt fremgangsmåder til deres fremstilling
US9017312B2 (en) 2009-09-10 2015-04-28 Taris Biomedical Llc Implantable device for controlled drug delivery
PL3884988T3 (pl) 2009-12-17 2025-09-08 Taris Biomedical Llc Urządzenie implantowalne z tolerancją wewnątrzpęcherzową
EP3795121A1 (en) 2010-08-05 2021-03-24 TARIS Biomedical LLC Ureteral stent drug delivery device
WO2012048114A1 (en) 2010-10-06 2012-04-12 Taris Biomedical, Inc. Time-selective bioresorbable or collapsible drug delivery systems and methods
JP2014503554A (ja) 2011-01-10 2014-02-13 タリス バイオメディカル,インコーポレイテッド 膀胱痛及び刺激性排尿の持続的治療の使用のためのリドカインレジメン
EP2670398B1 (en) 2011-02-04 2017-06-07 TARIS Biomedical LLC Implantable device for controlled release of low solubility drug
MX367070B (es) 2012-08-31 2019-08-05 Taris Biomedical Llc Sistemas de administracion de farmaco y metodos para el tratamiento de la prostata.
SG11201501424SA (en) 2012-08-31 2015-03-30 Taris Biomedical Llc Drug delivery systems and methods for treatment of bladder cancer comprising oxaliplatin
EP2719374A1 (en) * 2012-10-12 2014-04-16 Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen Drug delivery device
JP2016508842A (ja) 2013-03-05 2016-03-24 タリス バイオメディカル エルエルシー 装置の開口部を通じて制御された薬物放出のための薬物送達装置及び方法
EP2968120B1 (en) 2013-03-15 2026-01-14 TARIS Biomedical LLC Drug delivery devices and methods for drug delivery
KR102557326B1 (ko) 2013-03-15 2023-07-19 타리스 바이오메디컬 엘엘씨 약물-투과성 구성요소를 가지는 약물 전달 장치
KR102385603B1 (ko) 2013-08-19 2022-04-11 타리스 바이오메디컬 엘엘씨 다중 유닛 약물 전달 장치 및 방법
EP3065807A1 (en) 2013-11-05 2016-09-14 TARIS Biomedical LLC Osmotic drug delivery devices, kits, and methods
LT4124339T (lt) 2014-03-06 2025-11-10 Vaisto įvedimo sistemos ir būdai šlapimo pūslės vėžiui gydyti gemcitabinu
KR20220061253A (ko) 2014-06-26 2022-05-12 타리스 바이오메디컬 엘엘씨 탄성 폴리머-약물 매트릭스 시스템을 포함하는 방광내 약물 전달 장치 및 방법
WO2016172704A1 (en) 2015-04-23 2016-10-27 Taris Biomedical Llc Drug delivery devices with drug-permeable component and methods
PT3432970T (pt) * 2017-02-01 2021-05-26 Taris Biomedical Llc Dispositivos de administração de fármaco in vivo
BR112020000832A2 (pt) 2017-07-25 2020-07-21 Taris Biomedical Llc métodos para tratar metástase tumoral
CN112839653A (zh) 2018-08-01 2021-05-25 塔里斯生物医药公司 使用曲司氯铵治疗膀胱过度活动症的方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007517912A (ja) * 2004-01-13 2007-07-05 バソジェニックス ファーマシューティカルズ, インコーポレイテッド 心脈管および腎臓の適応症のための制御放出cgrp送達組成物
JP2008517031A (ja) * 2004-10-20 2008-05-22 ガルデルマ・リサーチ・アンド・デヴェロップメント 座瘡の維持療法におけるアダパレンの使用方法
JP2013534923A (ja) * 2010-06-22 2013-09-09 テバ ウィメンズ ヘルス インコーポレイテッド 過活動膀胱に関連する状態を治療する方法
JP2015529688A (ja) * 2012-09-18 2015-10-08 タリス バイオメディカル エルエルシー トロスピウムの使用による膀胱排尿機能障害及び他の下部尿路疾患の治療のための薬物送達システム及び方法
WO2017042370A1 (en) * 2015-09-10 2017-03-16 Assistance Publique - Hôpitaux De Paris Use of interleukin 2 for treating spondyloarthritis
JP2018070660A (ja) * 2016-10-27 2018-05-10 Eaファーマ株式会社 逆流性食道炎の再発抑制剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF CONTROLLED RELEASE, vol. 170, JPN6023026854, 2013, pages 161 - 166, ISSN: 0005099120 *

Also Published As

Publication number Publication date
US20230075003A1 (en) 2023-03-09
US12133913B2 (en) 2024-11-05
US11464734B2 (en) 2022-10-11
CN112839653A (zh) 2021-05-25
MX2021001264A (es) 2021-07-02
AU2019315957A1 (en) 2021-02-18
CA3107461A1 (en) 2020-02-06
EP3829582A1 (en) 2021-06-09
US20200060966A1 (en) 2020-02-27
WO2020028554A1 (en) 2020-02-06
JP2024164020A (ja) 2024-11-26
EP3829582A4 (en) 2022-04-27
BR112021001337A2 (pt) 2021-04-20
KR20210039403A (ko) 2021-04-09

Similar Documents

Publication Publication Date Title
US12133913B2 (en) Methods of treating overactive bladder using trospium
US11850244B2 (en) Drug delivery systems and methods for treatment of bladder dysfunction or disorder using trospium
RU2620032C2 (ru) Схема приема лидокаина для применения в продолжительном лечении боли в мочевом пузыре и раздражения при мочеиспускании
US10406335B2 (en) Drug delivery systems and methods for treatment of prostate
JP2021502347A (ja) ゲムシタビンを使用した膀胱癌の治療及び維持療法の方法
US10086034B2 (en) Compositions and methods for inducing urinary voiding and defecation
RU2832085C2 (ru) Способы лечения гиперактивного мочевого пузыря с применением троспия хлорида
BR122025013571A2 (pt) Usos de trópsio no tratamento de bexiga hiperativa e dispositivos intravesicais
HK40026424A (en) Drug delivery systems and methods for treatment of bladder voiding dysfunction and other lower urinary tract disorders by using trospium
HK40042011A (en) Drug delivery systems and methods for treatment of prostate

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220801

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220801

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230630

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230704

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230928

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231228

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240326

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240726

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240905

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240910